Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD StudyPosted by On

LONDON & MELBOURNE, Australia–(BUSINESS WIRE)–Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of Part B of its Phase 1 comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021. The positive results of this two-part Phase 1 trial demonstrate the tolerability

Source link


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.